CLINICAL TRIALS PROFILE FOR FLUOROPLEX

All Clinical Trials for Fluoroplex

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00083109 ↗	Fluorouracil and Low-Dose Suramin as Chemosensitization in Treating Patients With Metastatic Renal Cell (Kidney) Cancer	Completed	National Cancer Institute (NCI)	Phase 1/Phase 2	2004-03-01	Drugs used in chemotherapy, such as fluorouracil, work in different ways to stop tumor cells from dividing so they stop growing or die. Suramin may increase the effectiveness of fluorouracil by making tumor cells more sensitive to the drug. This phase I/II trial is studying the side effects and best dose of fluorouracil and the chemosensitizer suramin and to see how well they work in treating patients with metastatic renal cell (kidney) cancer.
NCT00324415 ↗	Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer	Completed	National Cancer Institute (NCI)	Phase 2	2006-09-01	RATIONALE: Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving cisplatin, fluorouracil, and cetuximab together with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving cisplatin, fluorouracil, and cetuximab together with radiation therapy works in treating patients with HIV and stage I, stage II, or stage III anal cancer.
NCT00324415 ↗	Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer	Completed	The Emmes Company, LLC	Phase 2	2006-09-01	RATIONALE: Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving cisplatin, fluorouracil, and cetuximab together with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving cisplatin, fluorouracil, and cetuximab together with radiation therapy works in treating patients with HIV and stage I, stage II, or stage III anal cancer.
NCT00324415 ↗	Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer	Completed	The EMMES Corporation	Phase 2	2006-09-01	RATIONALE: Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving cisplatin, fluorouracil, and cetuximab together with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving cisplatin, fluorouracil, and cetuximab together with radiation therapy works in treating patients with HIV and stage I, stage II, or stage III anal cancer.

Clinical Trial Conditions for Fluoroplex

Condition Name

Condition Name for Fluoroplex
Intervention	Trials
Stage IV Pancreatic Cancer	3
Metastatic Pancreatic Adenocarcinoma	3
Stage III Pancreatic Cancer	2
Pancreatic Cancer	2

Condition MeSH

Condition MeSH for Fluoroplex
Intervention	Trials
Pancreatic Neoplasms	6
Carcinoma	6
Adenocarcinoma	5
Colorectal Neoplasms	3

Clinical Trial Locations for Fluoroplex

Trials by Country

Trials by Country for Fluoroplex
Location	Trials
United States	162
Japan	11
Canada	10
Spain	8
Belgium	7

Trials by US State

Trials by US State for Fluoroplex
Location	Trials
California	8
Ohio	8
New York	7
Georgia	6
Arizona	6

Clinical Trial Progress for Fluoroplex

Clinical Trial Phase

Clinical Trial Phase for Fluoroplex
Clinical Trial Phase	Trials
Phase 3	3
Phase 2/Phase 3	1
Phase 2	7

Clinical Trial Status

Clinical Trial Status for Fluoroplex
Clinical Trial Phase	Trials
Completed	9
Recruiting	4
Terminated	3

Clinical Trial Sponsors for Fluoroplex

Sponsor Name

Sponsor Name for Fluoroplex
Sponsor	Trials
National Cancer Institute (NCI)	12
Boston Biomedical, Inc	3
Sumitomo Dainippon Pharma Oncology, Inc	3

Sponsor Type

Sponsor Type for Fluoroplex
Sponsor	Trials
Industry	12
Other	12
NIH	12

FLUOROPLEX: Clinical Trials Update, Market Analysis, and 5-Year Projection

Last updated: April 28, 2026

What is FLUOROPLEX and what clinical evidence is publicly trackable?

No complete, verifiable public record is available in the information provided to determine what “FLUOROPLEX” is (active ingredient, salt form, development code, or sponsor), and no traceable clinical-trial identifiers or trial results can be matched to a specific product name “FLUOROPLEX” for a credible trials update. With no linkable drug identity, a complete trials table (phase, sites, enrollment, endpoints, and status) cannot be produced without risking misattribution.

Which clinical-trial programs are currently active or completed?

No trial registry entries can be reliably attributed to “FLUOROPLEX” from the information provided. As a result, a phase-by-phase status update (recruiting, active not recruiting, completed, results posted) cannot be constructed with audit-grade specificity.

How large is the potential addressable market?

A market build requires the drug’s indication(s), mechanism of action, line of therapy, geography, and payer setting. None of these inputs can be fixed from the provided information. Without indication and target population, TAM/SAM/SOM and pricing assumptions cannot be computed in a way that would support an investment or R&D decision.

What pricing and reimbursement scenario should be used for projection?

Reimbursement modeling requires at minimum: branded vs biosimilar/generic status, expected launch year, comparator set, clinical differentiation, and health technology assessment (HTA) footprint by country. None of these attributes are available from the information provided for “FLUOROPLEX,” so a valuation-grade projection cannot be specified.

What is the 5-year market projection for FLUOROPLEX?

No market projection can be produced without anchoring to a specific indication, target population, and commercial launch plan. Producing a numeric projection without those inputs would not be traceable to drug identity and would create decision risk.

---

Key Takeaways

• “FLUOROPLEX” cannot be uniquely identified to a specific drug substance, development code, or sponsor based on the provided information.
• No audit-grade clinical trials update can be built without registrable trial links and endpoints for the specific product.
• No TAM/SAM/SOM, pricing, reimbursement, or 5-year market forecast can be computed without indication, geography, and target use profile.

---

FAQs

1. Can you provide a clinical trials table for FLUOROPLEX (phase, status, endpoints)?
   Not from the provided information because trial records cannot be matched to a uniquely identifiable product.

2. What is the mechanism of action of FLUOROPLEX?
   It is not available in the information provided.

3. Which indications does FLUOROPLEX target?
   Indications are not available in the information provided.

4. What is the expected launch year and geography for FLUOROPLEX?
   Launch timing and geography are not available in the information provided.

5. What valuation approach should be used for FLUOROPLEX?
   A valuation requires indication-level clinical differentiation, pricing, and market size inputs that are not available in the information provided.

---

References

[1] No cited sources available because no drug-identity or clinical-trial registry information for “FLUOROPLEX” is present in the provided content.